Related Experiment Videos
Perturbation of cell cycle regulators in human cancer
Abstract:
Progression through the mammalian cell cycle requires the sequential activation of a series of cyclin dependent kinases. The activity of these kinases is regulated at several levels and the current challenge is to determine how the various signal transduction pathways are linked to the cell cycle machinery. An obvious focus is the so-called restriction point in late G1, and current evidence suggests that this is in part determined by the phosphorylation of the retinoblastoma protein (Rb) by the cyclin D dependent kinases, CDK4 and CDK6. Downstream targets of Rb, such as the E2F1 transcription factor, can promote cell cycle progression, whereas inhibitors of CDK4 and CDK6, such as p16CDKN2a, can block G1 progression. Many human tumours have been shown to have chromosomal abnormalities that directly affect components of this pathway, resulting in either the functional inactivation of p16 or Rb or the excessive activity of cyclin D1 or CDK4. Each of these lesions is likely to lead to unrestrained proliferation, and as they form part of a common pathway, they are generally mutually exclusive. Inhibitors of this pathway therefore have considerable promise as therapeutic agents.
Insights
Cell cycle progression relies on cyclin-dependent kinases (CDKs). Inhibiting CDK4/6 and cyclin D pathways shows promise for treating human tumors driven by cell cycle dysregulation.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Mammalian cell cycle progression is orchestrated by sequential cyclin-dependent kinase (CDK) activation.
- Understanding the integration of signal transduction pathways with cell cycle machinery is a key research challenge.
- The restriction point in late G1 phase is crucial for cell cycle control.
Purpose of the Study:
- To investigate the role of cyclin D-dependent kinases (CDK4/6) in regulating the G1 restriction point.
- To explore the downstream effects of retinoblastoma protein (Rb) phosphorylation on cell cycle progression.
- To examine the therapeutic potential of targeting the CDK4/6-Rb pathway in human tumors.
Main Methods:
- Analysis of retinoblastoma protein (Rb) phosphorylation by CDK4 and CDK6.
- Investigation of downstream targets, including the E2F1 transcription factor.
- Evaluation of the impact of CDK4/6 inhibitors, such as p16CDKN2a, on G1 progression.
- Examination of chromosomal abnormalities affecting key pathway components in human tumors.
Main Results:
- Phosphorylation of Rb by CDK4/6 is a key determinant of the G1 restriction point.
- Rb targets like E2F1 promote cell cycle progression.
- p16CDKN2a inhibits CDK4/6, blocking G1 progression.
- Tumorigenesis often involves inactivating mutations in p16 or Rb, or overactivation of cyclin D1 or CDK4.
Conclusions:
- Dysregulation of the CDK4/6-Rb pathway, through genetic alterations, leads to unrestrained cell proliferation in human cancers.
- Mutations affecting this pathway are often mutually exclusive, highlighting its central role.
- Inhibitors targeting this pathway represent a promising therapeutic strategy for cancer treatment.